Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 528-533

  Acevedo Gadea, Carlos ^a   Santin, Alessandro D ^b   Higgins, Susan A ^b   Urva, Shweta ^c   Ratner, Elena ^b   Silasi, Dan Arin ^b   Azodi, Masoud ^b   Rutherford, Thomas ^b   Schwartz, Peter E ^b   Abu Khalaf, Maysa M ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Endometrial cancer; Everolimus; MTOR; Topotecan

Indexed keywords

EVEROLIMUS; TOPOTECAN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; ENDOMETRIUM CANCER; EPISTAXIS; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TOR SERINE-THREONINE KINASES;

EID: 84900459058     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000085     Document Type: Article

References (22)

1. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S105-S143.
2. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
3. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62:278-281.
4. Thigpen JT, Blessing JA, Homesley H, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;33:68-70.
5. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902-3908.
6. Finkler N, Holloway R. Phase II study of topotecan and cisplatinum for stages III and IV or for recurrent endometrial cancer. Proc Am Soc Clin Oncol. 2002;19:409a.
7. Miller DS, Blessing JA, Lentz SS, et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002;87:247-251.
8. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nature reviews. Nat Rev Drug Discov. 2006;5:671-688.
9. Squillace RM, Miller D, Cookson M, et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther. 2011;10:1959-1968.
10. Wolf J, Slomovitz BM. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer. 2005;15:411.
11. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116:5415-5419.
12. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in womenwith recurrent ormetastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29:3278-3285.
13. Nakashio A, Fujita N, Rokudai S, et al. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 2000;60:5303-5309.
14. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086-2092.
15. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38:57-63.
16. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001;19:3967-3975.
17. Tsikouras P, Bouchlariotou S, Vrachnis N, et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol. 2013;169:19.
18. MS Colombo N, Schwartz P, Kostka J, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007;25:5516.
19. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18:5856-5864.
20. Huang S, Liu LN, Hosoi H, et al. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. 2001;61:3373-3381.
21. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:747-759.
22. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010;117:473-476.